View Exam | PowerPak

1. A 78-year-old male presents with a 5-month history of worsening cough and blames it on his chronic obstructive pulmonary disease (COPD) that is controlled with chronic inhaled corticosteroids. His medical history also includes hyperlipidemia and hypertension. Which of the patient's characteristics and medical history are risk factors for NTM-LD?

A. Age, COPD, and chronic inhaled corticosteroids B. Age, male sex, and COPD C. Age, hyperlipidemia, and hypertension D. Age, chronic inhaled corticosteroids, and male sex

2. Following a chest CT, a single sputum sample from the patient is sent for mycobacterial testing and reveals a positive culture for MAC. Which is the most appropriate next step in the management of this patient according to guidelines?

A. Watchful waiting with treatment initiation upon worsening of symptoms B. Empirical therapy with a macrolide C. Therapy with a 3-drug regimen including a macrolide, ethambutol, and streptomycin D. Collect and culture a second sputum sample

3. The patient receives a diagnosis of noncavitary nodular macrolide-susceptible MAC. Which of the following is the most appropriate treatment regimen?

A. Daily therapy with a macrolide and ethambutol for at least 12 months B. Daily therapy with a macrolide, ethambutol, and rifampin for 18 months C. 3-times weekly therapy with a macrolide, ethambutol, and rifampin for at least 12 months after culture conversion D. 3-times weekly therapy with a macrolide, ethambutol, and IV amikacin for at least 12 months after culture conversion

4. The patient is treated with a therapeutic regimen recommended by the guidelines and undergoes periodic sputum sample testing several times to assess progress. At which time point would the patient be defined as having refractory MAC as a consequence of remaining sputum culture positive?

A. 3 months B. 6 months C. 9 months D. 12 months

5. In the CONVERT study, what percentage of patients with refractory MAC achieved culture conversion with amikacin liposome inhalation suspension plus guideline-based therapy after 4 months of treatment?

A. 42 B. 29 C. 14 D. 9 E. I am unaware of the CONVERT study

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Following a chest CT, a single sputum sample from the patient is sent for mycobacterial testing and reveals a positive culture for MAC. Which is the most appropriate next step in the management of this patient according to guidelines?

3. The patient receives a diagnosis of noncavitary nodular macrolide-susceptible MAC. Which of the following is the most appropriate treatment regimen?

4. The patient is treated with a therapeutic regimen recommended by the guidelines and undergoes periodic sputum sample testing several times to assess progress. At which time point would the patient be defined as having refractory MAC as a consequence of remaining sputum culture positive?

5. In the CONVERT study, what percentage of patients with refractory MAC achieved culture conversion with amikacin liposome inhalation suspension plus guideline-based therapy after 4 months of treatment?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Following a chest CT, a single sputum sample from the patient is sent for mycobacterial testing and reveals a positive culture for MAC. Which is the most appropriate next step in the management of this patient according to guidelines?

3. The patient receives a diagnosis of noncavitary nodular macrolide-susceptible MAC. Which of the following is the most appropriate treatment regimen?

4. The patient is treated with a therapeutic regimen recommended by the guidelines and undergoes periodic sputum sample testing several times to assess progress. At which time point would the patient be defined as having refractory MAC as a consequence of remaining sputum culture positive?

5. In the CONVERT study, what percentage of patients with refractory MAC achieved culture conversion with amikacin liposome inhalation suspension plus guideline-based therapy after 4 months of treatment?

« Return to Activity

Customers who Purchased
this Activity also Purchased